Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering SPC-15, its lead intranasal therapeutic for post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” encompasses both composition and method claims for the company’s proprietary approach to preventing or delaying stress-induced behavioral responses. This U.S. allowance follows a corresponding patent issued by the Japan Patent Office earlier this year.
A Notice of Allowance signifies that the USPTO has completed its examination and determined that the application meets all requirements for patentability, meaning the patent will be granted shortly. For Silo Pharma, this development is crucial as it advances SPC-15 through the development pipeline. The patent protection adds a significant asset to the company’s biopharmaceutical intellectual property portfolio, which already includes issued and allowed patents. In the highly competitive field of neuropsychiatric therapeutics, robust IP protection can provide a competitive edge, attract potential partners, and support long-term commercialization strategies.
The global burden of PTSD is substantial, with millions affected worldwide and limited effective treatment options. SPC-15’s intranasal delivery offers a novel approach that could improve patient compliance and target stress-induced fear and anxiety pathways more directly. By securing patent rights in the U.S. and Japan, Silo Pharma is positioning itself to protect its innovation in two major pharmaceutical markets. This move is particularly important as the company seeks to differentiate itself in a space where few novel therapies have emerged in recent years.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus includes underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Beyond SPC-15, the company’s portfolio features SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories. For more details on the patent allowance, see the full press release at https://ibn.fm/Hh4Z6.
The implications of this patent allowance extend beyond immediate legal protection. It validates Silo Pharma’s scientific approach and could facilitate future fundraising or partnership discussions. In the biotech sector, patents are often the cornerstone of valuation, especially for developmental-stage companies without marketed products. This allowance may also boost investor confidence, as it demonstrates tangible progress in a key program. Furthermore, the alignment with Japan’s patent grant suggests a strategic international focus, potentially easing expansion into Asian markets.
While the patent allowance is a positive step, challenges remain. Clinical trials, regulatory approvals, and commercialization hurdles lie ahead. However, the strengthening IP estate provides a foundation to navigate these challenges. For investors and stakeholders, this news underscores Silo Pharma’s commitment to addressing unmet needs in mental health. The latest updates on SILO can be found in the company’s newsroom at https://ibn.fm/SILO.
